NASDAQ · MCRB
Healthcare · Biotechnology
$1.77
Down-$0.18 (-9.23%)
Updated Nov 1, 2026, 10:48 AM
SID Score
2.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · MCRB
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
MCRB closed at $1.77 after 20 trading sessions, down 37.89% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $1.92 | $1.92 | $1.75 | $1.77 | 120.11K |
| Oct 29, 2026 | $1.90 | $2.0293 | $1.81 | $1.95 | 78.51K |
| Oct 28, 2026 | $1.77 | $1.93 | $1.675 | $1.79 | 87.5K |
| Oct 27, 2026 | $2.00 | $2.00 | $1.70 | $1.80 | 165.35K |
| Oct 26, 2026 | $2.11 | $2.185 | $1.98 | $1.98 | 53.07K |
| Oct 23, 2026 | $2.13 | $2.17 | $2.00 | $2.09 | 69.71K |
| Oct 22, 2026 | $2.29 | $2.30 | $2.02 | $2.13 | 132.2K |
| Oct 21, 2026 | $2.30 | $2.40 | $2.2609 | $2.30 | 41.77K |
| Oct 20, 2026 | $2.41 | $2.5499 | $2.31 | $2.31 | 66.98K |
| Oct 19, 2026 | $2.46 | $2.58 | $2.415 | $2.42 | 23.37K |
| Oct 16, 2026 | $2.56 | $2.56 | $2.422 | $2.46 | 38.57K |
| Oct 15, 2026 | $2.40 | $2.6099 | $2.40 | $2.53 | 24.61K |
| Oct 14, 2026 | $2.65 | $2.66 | $2.385 | $2.42 | 42.97K |
| Oct 13, 2026 | $2.66 | $2.66 | $2.51 | $2.53 | 44.06K |
| Oct 12, 2026 | $2.75 | $2.78 | $2.66 | $2.68 | 54.28K |
| Oct 9, 2026 | $2.65 | $2.75 | $2.58 | $2.71 | 79.41K |
| Oct 8, 2026 | $2.68 | $2.7243 | $2.42 | $2.63 | 213.36K |
| Oct 7, 2026 | $2.86 | $3.00 | $2.70 | $2.72 | 60.38K |
| Oct 6, 2026 | $2.875 | $3.0198 | $2.80 | $2.90 | 76.42K |
| Oct 5, 2026 | $2.91 | $2.91 | $2.81 | $2.85 | 63.3K |
The latest Smart Investors Daily articles mentioning MCRB.
Company
Market Activity
Research & News
MCRB research
Company profile and research snapshot.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 23, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 13, 2026 | Canaccord Genuity | Buy | — |
| Sep 24, 2025 | Canaccord Genuity | Buy | — |
| May 8, 2025 | Chardan Capital | Neutral | — |
| Mar 20, 2025 | Chardan Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 26, 2026
On October 22, 2026, Marella Thorell, Executive Vice President and Chief Financial Officer of Seres Therapeutics, Inc. (the "Company"), resigned from her positions as Executive Vice President and Chief Financial
Yahoo · Oct 15, 2026
Novel oral liquid formulation of SER-428 is designed for patients who cannot take oral capsules, including critically ill patients receiving nutrition via feeding tube SER-428 significantly reduced gastrointestinal abundance of clinically relevant pathogens in preclinical in vivo colonization models CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that preclinical data supporting the development o
Benzinga · Oct 15, 2026
Novel oral liquid formulation of SER-428 is designed for patients who cannot take oral capsules, including critically ill patients receiving nutrition via feeding tubeSER-428 significantly reduced gastrointestinal
Yahoo · Sep 8, 2026
CAMBRIDGE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading live biotherapeutics company, today announced that on September 4, 2026, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants consisting of stock options to purchase an aggregate of 4,200 shares of its common stock to two new employees. These stock options are subject to the terms of the Seres Therapeutics, Inc. 2022 Emp
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MCRB.
